Biomarkers in Idiopathic Juvenile Arthritis

Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02343770

Enrollment

Registered

2015-01-22

Start date

2015-06-30

Completion date

2016-12-31

Last updated

2015-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Juvenile Arthritis

Brief summary

Juvenile idiopathic arthritis (JIA) is the most common form of arthritis in children. The etiology is unknown. Several types of arthritis fall under the JIA heading. Oligoarticular JIA with antinuclear antibodies affects about half of all children. There 's no specific markers. Our purpose is to identify new markers in this pathology. The ProtoArray®Human Protein Microarray allows rapid and efficient detection of protein interaction using a suitable protein or small molecule probe. The investigators hope so detect novel potential autoantigen biomarkers specific in JIA.

Detailed description

We select 10 patients with inclusion criteria and 10 controls. We analyse their blood sample (5ml). The ProtoArray® Microarray allows to detect novel protein-protein interactions, to rapidly perform serum profiling using a sensitive method to detect potential autoantigen biomarkers. The ProtoArray® Human Protein Microarray is a high-density protein microarray containing thousands of purified human proteins for protein interaction screening.

Interventions

OTHERblood sample for identifying biomarkers

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 16 Years

Healthy volunteers

Yes

Inclusion criteria

for experimental group : * child age from 2 to 16 years * Oligoarticular JIA with antinuclear antibodies * with or without uveitis

Exclusion criteria

for experimental group : * immunosuppressive and biological therapy Inclusion Criteria for control group : * child age from 2 to 16 years

Design outcomes

Primary

Measure	Time frame	Description
identification of specific autoantigen biomarkers	1 day	Identify blood sampling biomarkers of juvenile idiopathic arthritis

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026